Physician profile
Marisa Nh Guillory
NPI 1942429279
$2,196.99
in general payments reported to CMS, 2019-2025
15 companies · $700 in 2025
The $700 reported for 2025 was more than what 76% of Sleep Medicine (Pediatrics) providers received nationally (typical 2025 total: $235).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.97 · 2020: $53.30 · 2022: $277 · 2023: $557 · 2024: $562 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.14 |
| Education | $454.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $767.83 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $720.37 | 2022-2025 | Wakix |
| Inspire Medical Systems, INC. | $177.77 | 2025 | Inspire |
| Resmed Corp | $94.68 | 2023-2024 | |
| Axsome Therapeutics, INC. | $80.23 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $67.07 | 2024-2025 | Lumryz |
| Itamar Medical INC | $55.63 | 2024-2025 | Watchpatone |
| Acclarent, INC | $53.30 | 2020 | |
| Alk-Abello, INC | $48.22 | 2022-2025 | Neffy, Ragwitek, Odactra |
| Hikma Pharmaceuticals USA | $29.29 | 2023-2024 | Ryaltris |
| Zoll Respicardia, INC. | $25.20 | 2023 | Remede System |
| Stryker Corporation | $22.87 | 2025 | Scopis Ent |
| 3b Medical, INC. | $19.03 | 2025 | Luna |
| Ars Pharmaceuticals Operations, INC. | $18.21 | 2025 | Neffy |
| Kaleo, INC. | $17.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Guillory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.